期刊文献+

乳腺癌中P53的表达与上皮-间质转化的相关性及其临床意义 被引量:6

Correlation and clinical significance of P53 expression with epithelial-mesenchymal transition in breast cancer
下载PDF
导出
摘要 目的:探讨乳腺癌组织中P53的表达和上皮-间质转化(EMT)的相互关系及其临床意义。方法:免疫组织化学法检测63例乳腺癌组织中P53、Twist、Snail、E-Cadherin、N-Cadherin、Vimentin和Fibronectin的表达情况,分析乳腺癌突变型P53蛋白表达与临床病理特征,患者预后和EMT发生之间的关系。结果:P53、Twist和Snail的阳性率以及EMT的发生率分别为44.4%(28/63)、54.0%(34/63)、68.3%(43/63)和41.3%(26/63)。乳腺癌P53表达与组织学分级相关(P<0.05),与其他临床病理特征无关(P>0.05)。P53与Twist、Snail的表达存在相关性,而Twist、Snail和EMT发生相关(P<0.05)。多因素分析显示,淋巴结转移、P53和EMT是乳腺癌患者预后的独立影响因素。结论:P53的表达与乳腺癌组织学分级和EMT的发生相关,是患者预后的独立影响因素,可作为乳腺癌治疗的重要靶点。 Objective:This study aims to investigate the correlation and significance between the expression of P53 and epitheli-al-mesenchymal transition (EMT) in breast cancer. Methods:The expression patterns of P53, Twist, Snail, E-cadherin, N-cadherin, Vi-mentin, and Fibronectin protein were detected via immunohistochemistry in 63 cases with breast carcinoma. The correlation of P53 pro-tein with clinicopathologic features and survival of breast carcinoma, as well as the relationship between the expression of P53 and EMT, was analyzed. Results:The expression rates of P53, Twist, Snail, and EMT are 44.4%(28/63), 54.0%(34/63), 68.3%(43/63), and 41.3%(26/63), respectively. The P53 protein expression is correlated with tumor grade (P〈0.05) but not with other clinicopatholog-ic features (P〉0.05). The expression of P53 is also correlated with the expression of Twist and Snail, which are associated with EMT (P〈0.05). Multivariate survival analysis reveals that lymph node metastasis, P53, and EMT are independent prognostic factors. Conclu-sion:The expression of P53 is correlated with tumor grade and EMT in breast cancer, which can be used as an independent prognostic factor. Therefore, P53 may be an effective target for breast cancer therapy.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第12期776-780,共5页 Chinese Journal of Clinical Oncology
基金 天津市应用基础及前沿技术研究计划项目资助(编号:12JCYBJC16100)~~
关键词 乳腺肿瘤 P53 上皮-间质转化 预后 免疫组织化学 breast neoplasms, P53, epithelial-mesenchymal transition, prognosis, immunohistochemistry
  • 相关文献

参考文献17

  • 1Dookeran KA, Dignam JJ, Ferrer K, et al. p53 as a marker of prog- nosis in African--American women with breast cancer[J]. Ann Surg Oncol, 2010, 17(5):1398-1405.
  • 2Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Gener- ation[J]. Cell, 2011, 144(5):646-674.
  • 3Jeong H, Ryu YJ, AnJ, et al. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-neg- ative phenotype[J]. Histopathology, 2012, 60(6B):E87-E95.
  • 4Walerych D, Napoli M, Collavin L, et al. The rebel angel: mutant p53 as the driving oncogene in breast cancer[J]. Carcinogenesis, 2012, 33 (11) :2007-2017.
  • 5张勤,刘红.P53在三阴性乳腺癌中的表达及临床意义[J].中国肿瘤临床,2011,38(4):214-217. 被引量:26
  • 6Trimboli AJ, Fukhlo K, de Bruin A, et al. Direct evidence for epithe- lial-mesenchyanal transitions in breast cancer[J]. Cancer Res, 2008, 68 (3):937-945.
  • 7Thiery JP, Acloque H, Huang RY, et al. Epithefial-mesenchyrnal transitions ha development and disease[J].Cell, 2009, 139(5):871--890.
  • 8Alexander NR, Tran NL, Rekapally H, et al. N--cadherin gene ex- pression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist 1 [J]. Cancer Res, 2006, 66(7) :3365-3369.
  • 9Siemens H Jackstadt R, Hunten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchy- mal transitions[J]. Cell Cycle. 2011, 10(24):4256-4271.
  • 10Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial-mes- enchymal transition through microRNAs targeting ZEB1 and ZEB2 [J].J Exp Med, 2011, 208(5):875-883.

二级参考文献10

  • 1杜长征,李惠平,马力文,付卫,王墨培,贾廷珍,赵红梅,侯宽永.中国乳腺癌患者p53表达临床生物学意义的Meta分析[J].中国癌症杂志,2005,15(6):514-517. 被引量:23
  • 2Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci U S A,2001,98(19):10869-10874.
  • 3Norbeng T,Klaar S,Karl G,et al.Increased p53 mutation frequency during tumor progression results from a breast cancer cohort[J].Cancer Res,2001,61(22):8317-8321.
  • 4Dookeran KA,Dignam JJ,Ferrer K,et al.p53 as a marker of prognosis in African-American women with breast cancer[J].Ann Surg Oncol,2010,17(5):1398-1405.
  • 5Chae BJ,Bae JS,Lee A,et al.p53 as a specific prognostic factor in triple-negative breast cancer[J].Jpn J Clin Oncol,2009,39(4):217-224.
  • 6Rakha EA,El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
  • 7Geisler S,Lonning PE,Aas T,et a1.Influence of TP53 gene alterations and cerbB2 expression on the response to treatment with doxorubicin in locally advanced breast cancer[J].Cancer Res,2001,61(6):2505-2512.
  • 8Malamou-Mitsi V,Gogas H,Dafni U,et al.Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J].Ann Oncol,2006,17(10):1504-1511.
  • 9Phil R,Ian S,Zanra M,et al.The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer[J].Int J Cancer,2006,120(6):1311-1317.
  • 10Sidoni A,Cavaliere A,Bellezza G,et al.Coexpression of HER-2/neu and p53 in breast cancer inentifies a subset with an aggressive biopathological profile[J].Tumori,2006,92(5):412-415.

共引文献25

同被引文献63

  • 1Research Center of Clinical Medicine,Affiliated Hospital of Nantong University,Nantong 226001,China (Yao M,Yao DF,Qiu LW,Wu W,Sai WL,Yang JL and Zhang HJ),Department of Oncology,Yancheng First People’s Hospital,Yancheng 224001,China (Bian YZ),Department of Oncology,Second Affiliated Hospital,Nanjing Medical University,Nanjing 210011,China (Zhang CG).Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2011,10(3):289-294. 被引量:52
  • 2Min Yao,Deng-Fu Yao,Yin-Zhu Bian,Wei Wu,Xiao-Di Yan,Dan-Dan Yu,Li-Wei Qiu,Jun-Ling Yang,Hai-Jian Zhang,Wen-Li Sai,Jie Chen.Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2013,12(2):171-179. 被引量:19
  • 3Schneider B P, Winer E P, Foulkes W D, et al. Triple-negative breast cancer: risk factors to potential targets [ J]. Clin Cancer Res, 2008,14(24) :8010 - 8.
  • 4Dent R, Trudean M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [ J ]. Clin Cancer Res, 2007,13 ( 15 Pt 1 ) :4429 - 34.
  • 5Hall J M, Lee M K, Newman B, et al. Linkage of early-onset fa- milial breast cancer to chromosome 17q21 [J]. Science, 1990, 250 (4988) : 1684 - 9.
  • 6Ralhan R, Kant J, Kreienberg R, et al. Links between DNA double strand break repair and breast cancer: accumulating evi- dence from both familial and nonfamilial cases[ J]. Cancer Lett, 2007,248( 1 ) :1 - 17.
  • 7Narod S A, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast cancer linkage consortium[ J]. Am J Hum Genet, 1995,56 ( 1 ) : 254 - 64.
  • 8Ford D, Easton D F, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium [J]. Am JHum Genet, 1998,62 ( 3 ) : 676 - 89.
  • 9Foulkes W D, Stefansson I M, Chappuis P O, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer [J]. J Natl Cancer Inst, 2003,95(19) :1482 -5.
  • 10Johannsson O T, Idvall I, Anderson C, et al. Tumor biological features of BRCAl-indueed breast and ovarian cancer[ J]. Eur J Cancer, 1997,33 (3) :362 - 71.

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部